////SYSTANE® Complete Has You Covered When It Comes to Your Dry Eye Patients’ Symptoms

SYSTANE® Complete Has You Covered When It Comes to Your Dry Eye Patients’ Symptoms

Walter O. Whitley, OD, MBA, FAAO

Director, Optometric Services,

Virginia Eye Consultants,

Norfolk, Virginia

Dr. Whitley was compensated by Alcon for his participation in this blog post.

SYSTANE® Complete Has You Covered When It Comes to Your Dry Eye Patients’ Symptoms

Dry eye affects an estimated 30 million people in the US and is one of the most common reasons people go to see their eye doctor.1 Dry eye symptoms can include blurred vision, burning and irritation, potentially reducing quality of life and productivity.2-4  

According to the recently published TFOS DEWS II Report, “Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.”5  The report acknowledged that aqueous-deficient and evaporative dry eye can co-exist. In aqueous deficient dry eye, the eye doesn’t produce enough tears. In evaporative dry eye, the eye produces tears but not enough lipids to prevent their evaporation.5 Estimates reveal that 30-70% of cases are neither purely aqueous nor evaporative, but mixed, exhibiting both causes.6 While it is important to identify both forms, it is even more important to understand that the two forms may require different treatments. Additionally, it is critical to evaluate and treat any underlying ocular surface inflammation which may exist in both forms. In such cases, addressing only tear production or evaporation provides inadequate relief.

One way to initially address diverse patient symptoms is to recommend a dry eye solution designed for all major types of dry eye, such as SYSTANE® Complete, which both adds to the tear film and prevents rapid evaporation.7,8 SYSTANE® Complete contains HP-guar, a non-ionic polymer that becomes a gel upon instillation and enhances the soothing effects of the drops. SYSTANE® Complete uses Alcon’s proprietary technology to provide increased concentrations of HP-guar, resulting in better coverage of the eye*9, 10 and long-lasting relief,7,11-13 and is formulated to induce minimal blur on instillation.14 My patients using SYSTANE® Complete report long-lasting relief. Either as initial therapy or adjunct therapy with anti-inflammatories and meibomian gland treatments, SYSTANE® Complete ― a single option for multiple dry eye symptomsworks for all major types of dry eye, providing better ocular surface coverage*, rapid hydration, and long-lasting relief.9,11,13,14

*Compared to SYSTANE® Balance Lubricant Eye Drops.9,14

References

  1. TFOS. What Is DEWS II. Available at http://www.tearfilm.org/dettreports-tfos_dews_ii_report/32_30/eng/. Accessed May 16, 2018
  2. Mertzanis P, Abetz L, Rajagopalan K, et al. The relative burden of dry eye in patients’ lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci. 2005;46:46-50.
  3. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409-415
  4. Barabino S, Labetoulle M, Rolando M, Messmer EM. Understanding symptoms and quality of life in patients with dry eye syndrome. Ocular Surf. 2016;14:365-376
  5. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276-283
  6. Jones L, Downie LE, Korb D et al. TFOS DEWS II Management and Therapy Report. Ocul Surf 2017; 15:575-628.
  7. Korb D, Blackie C, Meadows D, Christensen M, Tudor M. Evaluation of extended tear stability by two emulsion based artificial tears. Poster presented at the 6th International Conference of the Tear Film and Ocular Surface: Basic Science and Clinical Relevance, September 22-25, 2010, Florence, IT.
  8. Davitt, WF, Bloomenstein M, Christensen M, Martin AE. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation. J Ocul Pharmacol Ther. 2010;26(4):347-353.
  9. Data on file. Alcon; February 2017.
  10. Ogundele A, Ketelson H, et al. Preclinical evaluation of a novel hydroxypropyl-guar phospholipid nanoemulsion lubricant eye drop for dry eye disease. Poster presented at: The 36th World Ophthalmology Congress (WOC); June 16-19, 2018; Barcelona, Spain.
  11. Lane S, Paugh JR, Webb JR, Christensen MT. An evaluation of the in vivo retention time of a novel artificial tear as compared to a placebo control. Invest Ophthalmol Vis Sci. 2009;50(13):4679.
  1. Torkildsen G. The effects of lubricant eye drops on visual function as measured by the Inter-blink interval Visual Acuity Decay test. Clin Ophthalmol. 2009;3:501-506.
  2. Benelli U. SYSTANE® lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5:783-790.
  3. Ketelson H, Rangarajan R. Pre-clinical evaluation of a novel phospholipid nanoemulsion based lubricant eye drops. Invest Ophthalmol Vis Sci. 2017;58:3929.

© 2018 Novartis  12/18  US-SYS-18-E-1764b                                                                                                  

                                                       Sponsored by   

By |2018-12-10T00:00:00+00:00December 10th, 2018|Articles, Read, Walter O. Whitley|0 Comments

About the Author:

Leave A Comment

BrainCreatives I.T